Table 4.
Meta-analysis Results for response.
| Group | No. of studies | No. of participants | OR (95%CI) | P | Test for heterogeneity | |
|---|---|---|---|---|---|---|
| P | I2 | |||||
| All | 18 | 2024 | 1.20 (1.07-1.34) | 0.016 | 0.082 | 33.6% |
| mCRC | 12 | 1691 | 1.24 (1.05-1.48) | 0.014 | 0.060 | 42.2% |
| SCLC | 2 | 64 | 0.87 (0.57-1.33) | 0.514 | 0.458 | 0.0% |
| mNSCLC | 3 | 202 | 1.08 (0.71-1.63) | 0.726 | 0.127 | 51.5% |
| Asian | 12 | 2270 | 1.08 (0.82-1.42) | 0.168 | 0.019 | 51.7% |
| Caucasian | 5 | 1118 | 1.23 (1.06-1.42) | 0.006 | 0.669 | 0.0% |
| Retrospective | 4 | 538 | 1.54 (1.06-2.23) | 0.022 | 0.060 | 59.5% |
| Prospective | 12 | 1292 | 1.07 (0.93-1.22) | 0.343 | 0.511 | 0.0% |
mCRC, metastatic colorectal cancer; mNSCLC, metastatic non-small-cell lung cancer